Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
- None.
- None.
Insights
The recent announcement by Tevogen Bio regarding the successful completion of the proof-of-concept clinical trial for TVGN 489 represents a significant milestone in the field of immunotherapy. The ability of their ExacTcellTM technology to target and eliminate viruses in a high-risk population suggests a promising avenue for treating virally induced cancers. This is particularly noteworthy as it indicates a potential shift in the treatment paradigm for diseases such as cervical cancer, which is predominantly caused by HPV and certain lymphomas associated with EBV.
From an investment perspective, this development could signal a new growth trajectory for Tevogen Bio, especially if subsequent trials prove successful and result in marketable therapies. The application of their platform technology to a broader range of virally induced cancers could diversify their portfolio and possibly reduce the risk profile of their pipeline. However, the biotech sector is inherently risky, with high rates of clinical trial failure and significant capital requirements. Investors should monitor the progress of Tevogen's pipeline and consider the long development timelines typical of biopharmaceutical products.
The utilization of cytotoxic T lymphocytes (CTLs) in targeting virally driven cancers is a transformative approach that could potentially alter the standard of care in oncology. The statement by Dr. Flomenberg sheds light on the versatility of CTLs not only in preventative measures but also as a therapeutic intervention. The implications for patient care are profound; for instance, targeting HPV to prevent or reduce the severity of cervical cancer could lead to less invasive treatments and possibly better outcomes.
While the prospect of sparing patients from extensive surgical procedures is encouraging, it's important to remain cautiously optimistic until further clinical data is available. The integration of CTLs with existing cancer treatments could enhance efficacy but requires careful evaluation through clinical trials to establish safety and optimal protocols. As an oncologist, the potential for CTLs to be combined with other modalities opens up exciting research avenues and could eventually offer more personalized and effective treatment options for patients.
Tevogen Bio's strategic focus on leveraging its ExacTcellTM technology for the development of treatments targeting cancer-causing viruses places the company at the forefront of a niche but expanding segment within the biotech industry. The specificity of CTLs in targeting virally infected cells presents a unique competitive advantage, which could become a key differentiator in the market. This is particularly relevant as the industry shifts towards precision medicine and therapies that can offer higher efficacy with potentially fewer side effects compared to traditional chemotherapy.
Investors should consider the implications of Tevogen’s technology in the context of the broader industry trends towards targeted and personalized therapies. The scalability of their platform to address multiple virally induced cancers could provide a sustainable pipeline, which is a critical factor for long-term valuation. Nonetheless, it's essential to track the regulatory landscape and reimbursement policies that will ultimately influence the commercial success of Tevogen's products. Market adoption will hinge not only on clinical success but also on the company's ability to navigate these complex environments.
- Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities.
- Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma.
WARREN, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings (Tevogen) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer, explains the company’s oncology pipeline strategy.
“CTLs can be used for cancer treatments in several ways. Certain cancers are virally driven and can be targeted very similarly to targeting other viral infections. Our overwhelmingly positive experience with TVGN 489 gives us confidence that such an approach would succeed.
For example, virtually all cases of cervical cancer are caused by Human Papilloma Virus (HPV). After being infected by HPV, the virus remains in the cells before and after transformation to cancer. The virus can be targeted by CTLs before cancer transformation as a preventative step or after transformation as part of treatment. This approach could spare many women from surgical procedures and, in other cases, reduce the size and scope of a surgery to something more modest. In advanced cases, CTLs could be combined with other treatments.”
Dr. Flomenberg goes on to explain, “Some cancers that are not triggered by viruses can be targeted in other ways. The simplest next step would be to selectively coat the tumor cells with viral targets and use anti-viral CTLs to then eliminate them. Additional approaches are in development to take this approach even further in the treatment of other cancers.”
About Tevogen
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and twelve pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; Tevogen’s manufacturing plans; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this presentation and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
These factors include, but are not limited to: (i) the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; (ii) the outcome of any legal proceedings that may be instituted against Tevogen related to the Business Combination; (iii) changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (iv) changes in domestic and global general economic conditions; (v) the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; (vi) the risk that Tevogen may not be able to develop and maintain effective internal controls; (vii) costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; (viii) the failure to achieve Tevogen’s commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; (ix) the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (x) the ability to develop, license or acquire new therapeutics; (xi) that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xii) the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; (xiii) uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; (xiv) risks related to regulatory review, and approval and commercial development; (xv) risks associated with intellectual property protection; (xvi) Tevogen’s limited operating history; and (xvii) those factors discussed in Tevogen’s filings with the SEC and that that are contained in the Proxy Statement/Prospectus relating to the Business Combination.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is the significance of TVGN 489's proof-of-concept clinical trial completion?
What products is Tevogen Bio planning to develop using its ExacTcellTM technology platform?
Who is Neal Flomenberg and what is his role at Tevogen Bio?
How does Tevogen plan to use CTLs for cancer treatments?
What are some potential benefits of using CTLs in cancer treatment according to Dr. Flomenberg?
In what ways can cancers not triggered by viruses be targeted?
